Regulation of Akt Signaling by D2and D3Dopamine Receptors In Vivo

Abstract

The serine/threonine kinase Akt is a downstream target of dopamine receptor signaling that is inhibited/dephosphorylated in response to direct and indirect dopamine receptor agonists. Although pharmacological studies uncovered the involvement of D 2-class dopamine receptors in Akt regulation, they did not identify the role of individual receptor subtypes in this process. Here we used knock-out mice lacking the D 1, D 2, D 2 long, or D 3 dopamine receptors as well as a D 4 receptor-selective antagonist to address the function of each of these receptors in the regulation of Akt in vivo. Under basal conditions, D 2, D 2 long, and D 3 knock-out mice display enhanced striatal Akt activation, whereas D 1 knock-out mice and mice treated with the D 4 receptor antagonist L745870 (3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1 H-pyrrolo[2,3-b]pyridine trihydrochloride) have phospho-Akt levels comparable with those of normal control animals. Furthermore, both amphetamine and apomorphine lose their ability to inhibit Akt in D 2 knock-out mice but retain their normal effect on this signaling molecule in D 1 knock-out animals. Finally, D 3 knock-out mice show a reduced sensitivity of Akt-mediated signaling to dopaminergic drugs but retain the action of these drugs on Akt at high dose regimens. These results indicate that D 2 receptors are essential for the inhibition of Akt by dopamine and that D 3 receptors also participate in this signaling potentially by enhancing D 2 receptor response. Identification of the functions of individual dopamine receptor subtypes in Akt regulation may help the development of new pharmaceutical approaches for mental disorders related to abnormal dopamine transmission such as bipolar disorder and schizophrenia.